Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Italy's Piedmont region stops use of AstraZeneca vaccine batch

Sun, 14th Mar 2021 16:49

(Recasts and updates with new decision, details)

ROME, March 14 (Reuters) - Italy's northern region of
Piedmont said on Sunday said it would stop using a batch of
AstraZeneca coronavirus shots after a teacher died
following his vaccination on Saturday.

The region, around the northern city of Turin, had initially
suspended all AstraZeneca vaccines in order to identify and
isolate the batch from which the jab administered to the
teacher, from the town of Biella, came.

The decision, following similar moves elsewhere in Europe,
was precautionary and the region is awaiting the results of
checks which will verify whether there is a connection between
the death and the vaccination, the regional government said in
an online statement.

The statement did not specify what batch it had banned nor
did it say how the teacher died. Italian newspapers reported it
was batch ABV5811. A source close to the regional government
confirmed it was batch ABV5811.

The regional government's statement said that the Piedmont
region was also awaiting decisions from Italy's medicine's
agency Aifa and a regional health commission on the issue.

"It is an act of extreme prudence, while we verify whether
there is a connection. There have been no critical issues with
the administration of vaccines to date," Luigi Genesio Icardi,
head of regional health services, said in the statement.

Italy's medicine authority Aifa on Thursday banned the use
of doses of the AstraZeneca vaccine belonging to the ABV2856
batch. Sources told Reuters the decision had been taken after
the deaths of two men in Sicily.

Aifa had said that the ban was precautionary, adding that no
link had been established between the vaccine and subsequent
"serious adverse events".

Authorities in Denmark, Norway and Iceland have suspended
the use of the vaccine over blood clotting issues, while Austria
stopped using a batch of AstraZeneca shots last week while
investigating a death from coagulation disorders.

The European Medicines Agency has said there is no
indication that the events were caused by the vaccination, a
view that was echoed by the World Health Organisation on Friday.
AstraZeneca also said it had found no evidence of increased risk
of deep-vein thrombosis.

Ireland also temporarily suspended AstraZeneca's vaccine
"out of an abundance of caution" on Sunday, citing reports from
the Norwegian Medicines Agency regarding a cluster of serious
blood clotting in some recipients there.
Earlier on Sunday, Italian Health Minister Roberto Speranza
said vaccines in Italy and Europe were "effective and safe",
with all checks being carried out, when asked in an interview
about the ban.

(Reporting by Giulia Segreti; Editing by Nick Macfie and Jane
Merriman)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.